Lee Pharmaceuticals Subsidiary In-Licenses Dyax Corp. Drug for China Market
by Richard Daverman, PhD
February 8, 2013 -- CVie Therapeutics, a subsidiary of Hong Kong-based Lee's Pharma, has in-licensed China rights to Kalbitor®, a treatment for hereditary angioedema, from Dyax Corp. of the US. CVie will be responsible for securing regulatory approval of the drug in China. It has been available in the US since 2010. Lee’s markets western drugs for sale in mainland China; it also has an in-house R&D drug development operation. More details....
Stock Symbols: (HK: 00950) (NSDQ: DYAX)